

Table S2: Univariate Progression-free Survival Analysis

Variable	N	Progression	Median progression-free survival in months (95%CI)	1-year progression-free survival (95%CI)	HR(95%CI)	p-value*
Whole Cohort	159	113	11(10-12.5)	44%(35.7-52%)		
Age (increase by 5)					1.03(0.95-1.13)	0.479
T1Ds Delay						
No Delay	125	90	11.5(10.1-14.5)	47.1%(37.7-56%)	1	0.062
Delay	34	23	10(6.4-10.8)	31.9%(15.5-49.6%)	1.55(0.97-2.47)	
Stage						
III	50	33	12.5(10-16.2)	55.7%(39.9-68.9%)	1	0.124
IV	109	80	10.5(8.4-11.5)	38.6%(28.8-48.2%)	1.37(0.91-2.06)	
BRCA (30 missing not included)						
No mutation	101	75	10.5(8.3-11.5)	36.2%(26.5-46%)	1	0.038
BRCA mut/VUS	28	22	17.3(12.5-19.1)	74.5%(53.8-87%)	0.61(0.37-0.98)	
Preoperative Cycles (cont.)					1.29(1.1-1.51)	0.002
Charlson Score					1.02(0.9-1.15)	0.791
Chemotherapy Regimen						
Weekly Paclitaxel + Carboplatin	121	85	11.6(10-14.5)	47.6%(38-56.6%)	1	0.137
Others	38	28	10.5(7.2-11)	31.5%(16-48.3%)	1.38(0.9-2.12)	
Dose Reduction						
No	142	102	10.8(9.9-12.3)	43%(34.3-51.5%)	1	0.709
Yes	17	11	16.2(5.7-18.8)	53.1%(25-74.9%)	0.89(0.48-1.66)	
Complete Gross Resection						
No	53	46	8.7(6.3-10.2)	26.3%(14.9-39.2%)	1	<0.001
Yes	106	67	13.1(10.8-16.2)	53%(42.3-62.6%)	0.45(0.31-0.66)	
Optimal debulking						
No	20	19	5.6(3.5-10.2)	22%(7-42.3%)	1	0.003
Yes	139	94	11.5(10.1-14.4)	47.3%(38.2-55.8%)	0.48(0.29-0.78)	
T_{NACT} (Days)					1 (0.99-1.01)	0.513
T_{PoC} (Days)**					0.99 (0.98-1.01)	0.434

*p value is obtained by using Log-rank test for categorical variables and Wald test based on CoxPH model for continuous variables

**Analysis performed using landmark analysis